AstraZeneca's phase III trial results for tozorakimab in treating chronic obstructive pulmonary disease (COPD) showed significant reduction in flare-ups, especially in former smokers. The drug met its primary endpoint with a 29% to 34% reduction in exacerbations and showed stronger results in patients with high eosinophil counts compared to competitors. Citi values the drug's peak sales potential at $7 billion, nearly double the consensus estimate, and maintains a 'buy' rating on AstraZeneca stock. This optimistic outlook is supported by the drug's broad potential use across patient groups without the need for eosinophil testing.
AstraZeneca remains a strong long-term Buy due to its robust product lineup and promising pipeline, aiming for $80 billion in revenues by 2030. The company currently has 14 blockbuster drugs and expects up to 12 more from its pipeline by decade's end...
Jefferies estimates a 59% probability that AstraZeneca's kidney drug zibotentan will succeed in the phase 3 ZENITH-HP trial, with results expected in the first half of 2027. The trial tests zibotentan combined with Farxiga in patients with high prote...
Oracle and AstraZeneca have entered a collaboration to combine AstraZeneca's scientific expertise with Oracle's AI, cloud, and real-world data capabilities. The partnership aims to accelerate clinical trials by helping clinicians identify eligible pa...
